Skip to main content

Table 1 Clinical characteristics of 129 MDS patients based on the mutation status of spliceosomal genes

From: The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts

Characteristics SF3B1wt (n = 120, 93.0 %) SF3B1mut (n = 9, 7.0 %) P U2AF1wt (n = 119, 92.2 %) U2AF1mut (n = 10, 7.8 %) P SRSF2wt (n = 116, 89.9 %) SRSF2mut (n = 13, 10.1 %) P
Age (years)a 63.4 ± 11.9 67.9 ± 19.1 0.295 63.6 ± 12.5 63.8 ± 11.8 0.975 62.8 ± 12.7 71.5 ± 5.5 0.000
Sex    0.730    0.183    0.381
 Male, n (%) 67 (55.8) 4 (44.4)   63 (52.9) 8 (80.0)   62 (53.4) 9 (70.2)  
 Female, n (%) 53 (44.2) 5 (55.6)   56 (47.1) 2 (20.0)   54 (46.6) 4 (30.8)  
Blood countsa          
 WBC (× 103/μl) 5.6 ± 14.3 3.7 ± 1.8 0.700 5.5 ± 14.4 5.1 ± 4.6 0.935 5.6 ± 14.6 4.2 ± 2.7 0.734
 Neutrophil (× 103/μl) 3.4 ± 12.0 1.5 ± 1.3 0.650 3.2 ± 12.1 3.4 ± 3.9 0.960 3.4 ± 12.3 1.9 ± 1.9 0.672
 Hemoglobin (g/dl) 9.7 ± 2.2 9.2 ± 2.3 0.556 9.7 ± 2.2 8.4 ± 2.0 0.063 9.7 ± 2.3 9.4 ± 1.8 0.657
 Platelet (× 103/μl) 95 ± 91 168 ± 151 0.183 100 ± 98 92 ± 87 0.806 100 ± 100 91 ± 67 0.734
 Bone marrow blasts (%) 5.3 ± 5.3 3.8 ± 5.0 0.398 5.0 ± 5.2 7.7 ± 6.2 0.123 5.2 ± 5.4 5.6 ± 4.3 0.783
WHO subtype, n (%)    0.303    0.516    0.094
 RCUD 18 (15.0) 1 (11.1)   19 (16.0) 0 (0.0)   18 (15.5) 1 (7.7)  
 RCMD 51 (42.5) 5 (55.6)   52 (43.7) 4 (40.0)   50 (43.1) 6 (46.2)  
 RAEB-1 15 (12.5) 1 (11.1)   13 (10.9) 3 (30.0)   11 (9.5) 5 (38.5)  
 RAEB-2 29 (24.2) 1 (11.1)   27 (22.7) 3 (30.0)   29 (25.0) 1 (7.7)  
 MDS-U 1(0.8) 0 (0.0)   1 (0.8) 0 (0.0)   1 (0.9) 0 (0.0)  
 MDS associated with isolated del(5q) 1 (0.8) 1 (11.1)   2 (1.7) 0 (0.0)   2 (1.7) 0 (0.0)  
 Hypoplastic MDS 5 (4.2) 0 (0.0)   5 (4.2) 0 (0.0)   5 (4.3) 0 (0.0)  
Karyotype, n (%)    0.013    0.022    0.048
 Normal 87 (72.5) 6 (66.7)   87 (73.1) 6 (60.0)   86 (74.1) 7 (53.8)  
 -Y only 3 (2.5) 0 (0.0)   3 (2.5) 0 (0.0)   3 (2.6) 0 (0.0)  
 −5 or del(5q) 2 (1.7) 1 (11.1)   3 (2.5) 0 (0.0)   3 (2.6) 0 (0.0)  
 del(11q) 1 (0.8) 0 (0.0)   1 (0.9) 0 (0.0)   0 (0.0) 1 (7.7)  
 del(20q) 0 (0.0) 1 (11.1)   1 (0.9) 0 (0.0)   1 (0.9) 0 (0.0)  
 −7 1 (0.8) 0 (0.0)   0 (0.0) 1(10.0)   1 (0.9) 0 (0.0)  
 Complex (≥3) 11 (9.2) 0 (0.0)   11 (9.2) 0 (0.0)   8 (6.9) 3 (23.1)  
 Other 15(12.5) 1 (11.1)   13 (10.9) 3 (30.0)   14 (12.0) 2 (15.4)  
IPSS-R risk classification, n (%)    0.133    0.270    0.505
 Very low 14 (11.8) 1 (11.1)   15 (12.6) 0 (0.0)   14 (12.1) 1 (7.7)  
 Low 25 (20.8) 5 (55.6)   29 (24.4) 1 (10.0)   29 (25.0) 1 (7.7)  
 Intermediate 40 (33.3) 2 (22.2)   39 (32.8) 3 (30.0)   36 (31.0) 6 (46.2)  
 High 31 (25.8) 0 (0.0)   26 (21.8) 5 (50.0)   28 (24.1) 3 (23.1)  
 Very high 10 (8.3) 1 (11.1)   10 (8.4) 1 (10.0)   9 (7.8) 2 (15.3)  
  1. aMean ± SD
  2. Statistical significance is indicated by boldface type
  3. wt, wild type; mut, mutated; WBC, white blood cell; WHO, World Health Organization; MDS, myelodysplastic syndrome; RCUD, refractory cytopenia with unilineage dysplasia; RCMD, refractory cytopenia with multilineage dysplasia; MDS-U, myelodysplastic syndrome-unclassifiable; RAEB, refractory anemia with excess of blasts; del, deletion; IPSS-R, revised International Prognostic Scoring System